ATE410696T1 - Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis - Google Patents

Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis

Info

Publication number
ATE410696T1
ATE410696T1 AT05759896T AT05759896T ATE410696T1 AT E410696 T1 ATE410696 T1 AT E410696T1 AT 05759896 T AT05759896 T AT 05759896T AT 05759896 T AT05759896 T AT 05759896T AT E410696 T1 ATE410696 T1 AT E410696T1
Authority
AT
Austria
Prior art keywords
protein
aggregation
compound
antiprion
sift
Prior art date
Application number
AT05759896T
Other languages
English (en)
Inventor
Uwe Bertsch
Armin Giese
Hans Kretzschmar
Paul Tavan
Thomas Hirschberger
Jan Bieschke
Petra Weber
Konstanze Winklhofer
Joerg Tatzelt
F Hartl
Gerda Wuensch
Tobias Hoegen
Original Assignee
Univ Muenchen L Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen L Maximilians filed Critical Univ Muenchen L Maximilians
Application granted granted Critical
Publication of ATE410696T1 publication Critical patent/ATE410696T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05759896T 2004-05-24 2005-05-24 Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis ATE410696T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04012254 2004-05-24

Publications (1)

Publication Number Publication Date
ATE410696T1 true ATE410696T1 (de) 2008-10-15

Family

ID=35451505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05759896T ATE410696T1 (de) 2004-05-24 2005-05-24 Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis

Country Status (5)

Country Link
US (1) US20100029773A1 (de)
EP (1) EP1751553B1 (de)
AT (1) ATE410696T1 (de)
DE (1) DE602005010241D1 (de)
WO (1) WO2005116640A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE523788T1 (de) 2006-06-08 2011-09-15 Fu Berlin ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN
RU2461377C2 (ru) * 2007-07-12 2012-09-20 Эйкьюмен Фамэсьютиклз, Инк. Способ улучшения когнитивной функции (варианты)
MX2010000369A (es) * 2007-07-12 2010-07-02 Acumen Pharmaceuticals Inc Metodos para mejorar la funcion cognitiva usando compuestos no peptidicos.
US8962677B2 (en) 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
MX2010000370A (es) * 2007-07-12 2010-07-02 Acumen Pharmaceuticals Inc Metodos para inhibir la formacion de ligandos difusibles beta-amiloides usando compuestos de acilhidrazida.
EP2170322B1 (de) * 2007-07-12 2013-02-13 Acumen Pharmaceuticals, Inc. Verfahren zur modifizierung von amyloid-oligomeren mit nicht-peptidischen verbindungen
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
WO2009079566A2 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
KR101366372B1 (ko) 2012-01-30 2014-02-25 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
GB201303507D0 (en) * 2013-02-27 2013-04-10 Hollfelder Florian Assays
WO2021225982A1 (en) * 2020-05-04 2021-11-11 Children's Hospital Medical Center Sos1 allosteric site targeting
US12172948B2 (en) * 2020-11-12 2024-12-24 Oregon State University Molecular probe for selective detection of copper (II) ions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2001025192A1 (en) * 1999-10-06 2001-04-12 Melacure Therapeutics Ab Guanidine derivatives and their use in the production of a medicament for blocking xanthine oxidase/dehydrogenase
EP1687641A2 (de) * 2003-09-25 2006-08-09 Acadia Pharmaceuticals Inc. Behandlung neuropathischer schmerzen mit neuropeptid-ff-rezeptor-2-agonisten

Also Published As

Publication number Publication date
WO2005116640A3 (en) 2006-03-09
EP1751553A2 (de) 2007-02-14
WO2005116640A2 (en) 2005-12-08
DE602005010241D1 (de) 2008-11-20
US20100029773A1 (en) 2010-02-04
EP1751553B1 (de) 2008-10-08

Similar Documents

Publication Publication Date Title
DE602005010241D1 (de) Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis
CA2395724A1 (en) Nucleic acids, proteins, and antibodies
WO2005005462A3 (en) Blys antagonists and uses thereof
BRPI0812875A2 (pt) " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".
ATE401342T1 (de) Verfahren und materialien zum nachweis und zur messung von durch freie radikale verursachten schäden
DE60129239D1 (de) Kit und verfahren zur bestimmung von protein esm-1
DK1485481T3 (da) Fflourescerende protein fra Aequorea Coerulescens og anvendelser deraf
DK1565559T3 (da) Fluorescerende proteiner og chromoproteiner fra ikke aequorea hydrozoa arter samt fremgangsmåder til anvendelse deraf
DE60333486D1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
DE602004023766D1 (de) Dot1-histon-methyltransferasen als ziel zur identifizierung von therapeutika gegen leukämie
Ehrnhoefer et al. A quantitative method for the specific assessment of caspase-6 activity in cell culture
ATE483981T1 (de) Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion
EP1265073A3 (de) Verfahren zum Nachweis von der Plasmakonzentration von freien Arzneimitteln
JP2007082546A (ja) 毒性作用のマーカーとしてのｆａｂｐ４
ATE331786T1 (de) Matrix-metalloprotease
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
DE602004005859D1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
WO2007095378A3 (en) Mass tagging for quantitative analysis of biomolecules using 13c labeled phenylisocyanate
WO2006094185A3 (en) Quantification of proteins
DE602004019180D1 (de) Methode zur Identifizierung von unbekannten Proteinen mittels zwei-dimensionaler Auftrennung und Verwendung von Markern
US20070037143A1 (en) Method for screening for protease modulators
Shimazaki et al. Isolation and analysis of amyloid-β 1-42 monomer and oligomers in liquid droplets using an immunoaffinity membrane
WO2006089801A3 (de) Verfahren zum redox-potential-abhängigen nachweis von targetmolekülen durch wechselwirkende polypeptide
FR2857098B1 (fr) Procede de mise en evidence d'un evenement moleculaire dans une cellule grace a des proteines marqueurs fluorescentes.
Konopska et al. Characterization of chicken cystatin binding to rat renal brush-border membranes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties